⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 1, 2024Drugs - Real World OutcomesOpen Access

Relationship Between Clozapine and Non-Hematological Malignant Tumors: A Pharmacovigilance Analysis Using the FDA Adverse Event Reporting System Database

Yuichi Uwai Tomohiro Nabekura

View Full Paper

Ask AI

Bookmark

Share

Abstract

Clozapine shows higher efficacy against treatment-resistant schizophrenia than other antipsychotics. This study aimed to investigate whether clozapine is associated with the risk of non-hematological malignant tumors, utilizing the US Food and Drug Administration (FDA) Adverse Event Report System (FAERS) database.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Uwai et al. (2024) studied this question.

synapsesocial.com/papers/68e70efbb6db643587688704 https://doi.org/10.1007/s40801-024-00417-2

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Risk and management of cancer in clozapine users: A systematic reviewSystematic Review · 2026 · 3 citations
2Association Between Clozapine Exposure and Risk of Hematologic Malignancies in Veterans With Schizophrenia2024 · 6 citations
3Clozapine-associated adverse drug reactions in 38,349 psychiatric inpatients: drug surveillance data from the AMSP project between 1993 and 20162024 · 10 citations
4Adverse Drug Reactions in Relation to Clozapine Plasma Levels: A Systematic Reviewsystematic_review · 2022 · 52 citations
5A Pharmacovigilance Study on Clozapine in the Food and Drug Administration Adverse Event Reporting System: A Regional Comparative Analysis2024 · 7 citations